A compound that is selected from the group consisting of 3-(3,4-dichloroanilino)-3-oxopropanoic acid (hereinafter “DCOPA”); N-methyl-DCOPA; N,2-dimethyl-DCOPA; 2-methyl-DCOPA; isobutyl-DCOPA; N-methyl-isobutyl DCOPA; 3-(3,4-bibromoanilino)-3-oxopropanoic acid; and analogs of DCOPA; and analogs of 3-(3,4-bibromoanilino)-3-oxopropanoic acid; and pharmaceutically acceptable salts of these compounds, are disclosed. A method of controlling bone erosion in a patient comprising administering to the patient a therapeutically effective amount of at least one of these compounds, or a pharmaceutically acceptable salt of at least one of these compounds, is provided. A method of reducing inflammation in a patient having an inflammatory condition comprising administering to the patient a therapeutically effective amount of at least one of these compounds, or a pharmaceutically acceptable salt of at least one of these compounds is provided.

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

The invention discloses a method for the preparation of fluoro alkylated compounds by homogeneous Ni catalyzed fluoro alkylation with fluoro alkyl halides in the presence of a base.

The invention discloses a method for the preparation of fluoro alkylated compounds by homogeneous Ni catalyzed fluoro alkylation with fluoro alkyl halides in the presence of a base.

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

A curing agent composition contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C., and at least one halo-substituted diethyltoluenediamine, in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. A curable resin composition contains at least one epoxy compound having at least two epoxide groups per molecule of the epoxy compound and the curing agent composition. Methods for inhibiting phase separation of a curing agent composition or curable resin composition that contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C. include a step of adding to the respective composition at least one halo-substituted diethyltoluenediamine in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. The compositions and methods are useful in making fiber reinforced resin matrix composite articles.

A curing agent composition contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C., and at least one halo-substituted diethyltoluenediamine, in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. A curable resin composition contains at least one epoxy compound having at least two epoxide groups per molecule of the epoxy compound and the curing agent composition. Methods for inhibiting phase separation of a curing agent composition or curable resin composition that contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C. include a step of adding to the respective composition at least one halo-substituted diethyltoluenediamine in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. The compositions and methods are useful in making fiber reinforced resin matrix composite articles.

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: ##STR00001## The compounds are useful for treating inflammatory and autoimmune diseases.

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: ##STR00001## The compounds are useful for treating inflammatory and autoimmune diseases.